Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Study of Neoadjuvant Immune Checkpoint Inhibitors in Urothelial Cancer

Next Previous
X
Search
Trial Profile

Phase 2 Study of Neoadjuvant Immune Checkpoint Inhibitors in Urothelial Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary)
  • Indications Adenocarcinoma; Bladder cancer; Pelvic cancer; Renal cancer; Squamous cell cancer; Ureteral neoplasms; Urogenital cancer
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms ABACUS-2

    • Most Recent Events

    • 03 Sep 2024 Status changed from active, no longer recruiting to completed.
    • 24 Oct 2023 Results (n=23)efficacy and safety of neoadjuvant atezolizumab prior to cystectomy in patients with non-urothelial, bladder cancer presented at the 48th European Society for Medical Oncology Congress
    • 02 Aug 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top